Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesAmortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - Deferred ChargesCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

Celularity (CELU) Shares Outstanding (2020 - 2025)

Celularity (CELU) has disclosed Shares Outstanding for 6 consecutive years, with $28.8 million as the latest value for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 27.9% year-over-year to $28.8 million; the TTM value through Dec 2025 reached $28.8 million, up 27.9%, while the annual FY2025 figure was $28.8 million, 27.9% up from the prior year.
  • Shares Outstanding hit $28.8 million in Q4 2025 for Celularity, up from $28.2 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $144.5 million in Q3 2022 and bottomed at -$90834.0 in Q2 2021.
  • Average Shares Outstanding over 5 years is $43.1 million, with a median of $22.0 million recorded in 2024.
  • Year-over-year, Shares Outstanding soared 136022.8% in 2021 and then crashed 88.02% in 2023.
  • Celularity's Shares Outstanding stood at $12.4 million in 2021, then increased by 19.8% to $14.9 million in 2022, then surged by 30.12% to $19.4 million in 2023, then increased by 16.35% to $22.5 million in 2024, then increased by 27.9% to $28.8 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $28.8 million, $28.2 million, and $24.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.